Skip to main content
SpringerLink
Log in

Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In this study, we aimed to investigate the diagnostic and prognostic roles and the effects of chemotherapy of serum proinflammatory cytokines consisting of IL-6, TNF-α, CRP, and leptin levels in patients with advanced-stage non-small cell lung cancer. Twenty-eight patients newly diagnosed of non-surgical advanced non-small cell lung cancer and 15 healthy controls were included. All patients with good performance status were treated with combination therapy consisting of cisplatin plus vinorelbine chemotherapy. Blood samples were obtained in fasting conditions before chemotherapy first and after two cycles of chemotherapy. IL-6 and TNF-α immunoassays employ the quantitative sandwich enzyme immunoassay technique. Leptin (Sandwich) ELISA is a solid-phase enzyme-linked immunosorbent assay based on the sandwich principle. CRP is a photometric immunoturbidimetric test. Most of the patients were elderly, male predominance, good performance status, and no or less than 10% weight loss. Higher serum TNF-α (p<0.001) and CRP (p<0.001), and lower leptin (p=0.021) levels in patients than in controls. Serum IL-6 cytokine (p=0.693) levels were not significantly different. No statistically significant relationships between investigated serum parameters and various characteristics of patient and disease. Likewise, serum levels of leptin, IL-6, TNF-α, and CRP were all similar in lung cancer patients independently from severity of weight loss (p>0.05). A direct relationship was found between serum IL-6 and TNF-α levels (r=0.530, p=0.004). We found that both serum leptin (p=0.046) and IL-6 (p=0.002) levels were decreased owing to the chemotherapy effect independently from chemotherapy response. However, serum TNF-α and CRP levels were not changed by the chemotherapy effect. The stage of the disease, serum LDH levels, performance status, and responsiveness to chemotherapy yielded prognostic value. Only serum IL-6 levels out of the parameters showed a trend (p=0.06) related to a worse prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dy GK, Adjei AA. Novel targets for lung cancer therapy: Part II. J Clin Oncol 2002;20(13):3016–3028.

    Article  PubMed  CAS  Google Scholar 

  2. Aljada IS, et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 2004;22(16):3218–3229.

    Article  PubMed  CAS  Google Scholar 

  3. Matanic D, et al. Cytokines in patients with lung cancer. Scand J Immunol 2003;57(2):173–178.

    Article  PubMed  CAS  Google Scholar 

  4. Alexandrakis MG, et al. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med 2002;96(8):553–558.

    Article  PubMed  CAS  Google Scholar 

  5. Dinarello CA. Proinflammatory cytokines. Chest 2000;118: 503–508.

    Article  PubMed  CAS  Google Scholar 

  6. Larric JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-alfa. FASEB J 1990;4: 3125–3223.

    Google Scholar 

  7. Lucas R, et al. Both TNF receptors are required for direct TNF mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol 1998;28: 3577–3586.

    Article  PubMed  CAS  Google Scholar 

  8. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10: 573–580.

    Article  PubMed  CAS  Google Scholar 

  9. Chouaib S, Asselin-Pautrel C, Marni-Chouaib F, Cainard A, Blay Y. The host tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18: 493–497.

    Article  PubMed  CAS  Google Scholar 

  10. Del Prete G, Romagnani S. Human Th1 and Th2 cells functional properties, regulation of development and role in disease. In: T cell subsets and cytokine interplay in infectious diseases. Karger:Basel, 1996, pp. 18–26.

    Google Scholar 

  11. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91(12):1993–1995.

    Article  PubMed  CAS  Google Scholar 

  12. Kato K, et al. The value of serum C-reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer. Nihon Kokyuki Gakkai Zasshi 2000;38(8):575–580.

    PubMed  CAS  Google Scholar 

  13. Mantovani G, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 2001;79(7):406–414.

    Article  PubMed  CAS  Google Scholar 

  14. Harrold JA. Leptin leads hypothalamic feeding circuits in a new direction. Bioessays 2004;26(10):1043–1045.

    Article  PubMed  CAS  Google Scholar 

  15. Yanagawa H, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995;71(5):1095–1098.

    PubMed  CAS  Google Scholar 

  16. DeVita F, Orditura M, Auriemma A, Infusino S, Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 1998;17(4):413–417.

    CAS  Google Scholar 

  17. Martin F, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11(1):80–86.

    Article  PubMed  CAS  Google Scholar 

  18. Wojciechowska-Lacka A, Adamiak E, Stryczynska G, Lacki JK. Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report. Yale J Biol Med 1997;70(2):139–148.

    PubMed  CAS  Google Scholar 

  19. Katsumata N, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996;2(3):553–559.

    PubMed  CAS  Google Scholar 

  20. Orditura M, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002;22(11):1129–1135.

    Article  PubMed  CAS  Google Scholar 

  21. Tormo CA, et al. Prognostic value of the nutrition status and pro-inflammatory cytokines (IL-1, TNF-alpha and IL-6) in critically ill patients. Ann Med Interna 1999;16(11):562–568.

    Google Scholar 

  22. Milroy R, Shapiro D, Shenkin A, Banham SW. Acute phase reaction during chemotherapy in small cell lung cancer. Br J Cancer 1989;59(6):933–935.

    PubMed  CAS  Google Scholar 

  23. Niiya M, et al. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 2003;52(5):391–398.

    Article  PubMed  Google Scholar 

  24. Endo S, et al. Preoperative chemotherapy increases cytokine production after lung cancer surgery. Eur J Cardiothorac Surg 2004;26(4):787–791.

    Article  PubMed  Google Scholar 

  25. Staal-van den Brekel AJ, et al. The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer 1997;76(12):1630–1635.

    PubMed  CAS  Google Scholar 

  26. Aleman MR, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002;19(1):21–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istanbul Universitesi, Onkoloji Enstitusu, Capa, 34390, Istanbul, Turkey

    Faruk Tas, Derya Duranyildiz, Andac Argon, Hilal Oğuz, Hakan Camlica, Vildan Yasasever & Erkan Topuz

Authors
  1. Faruk Tas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derya Duranyildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andac Argon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hilal Oğuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hakan Camlica
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vildan Yasasever
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faruk Tas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tas, F., Duranyildiz, D., Argon, A. et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22, 353–358 (2005). https://doi.org/10.1385/MO:22:4:353

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:4:353

Key Words

Search

Navigation